Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study ...
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial...
Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor...
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Kevin Kalinsky, MD, of Winship Cancer Institute at Emory University, discuss phase II findings from the MAINTAIN trial, which showed a benefit in progression-free survival for patients with hormone receptor–positive/HER2-negative...
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses what she considers to be the most notable presentations at the 2021 San Antonio Breast Cancer Symposium. They include the focus on early-stage disease, especially in the TEXT/SOFT, RxPonder, and KEYNOTE-522 trials, as well as...
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The ...
Rosenberg et al found that the proportion of women diagnosed with breast cancer at age ≤ 40 years who have undergone BRCA1 and BRCA2 testing has increased during recent years. These findings, which were reported in JAMA Oncology, were part of the ongoing prospective Helping Ourselves, Helping...
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with...
Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.
Patients deciding to undergo contralateral prophylactic mastectomy as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removing the unaffected breast has not been shown to increase survival, and the more aggressive procedure is associated with...
Researchers seeking to determine why breast cancers are more deadly in young women found that although only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, delays in seeking care are more common in women with...
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...